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Pharmacogenomics in early-phase clinical  
development
A genomic biomarker is defined as ‘a measur-
able DNA and/or RNA characteristic that is an 
indicator of normal biologic processes, patho-
genic processes and/or response to therapeutic or 
other interventions’. Pharmacogenomics (PGx) 
is defined as ‘the study of variations of DNA and 
RNA characteristics as related to drug response’. 
Pharmacogenetics is a subset of PGx and is defined 
as ‘the study of variations in DNA sequence as 
related to drug response’ [1]. Another way of 
thinking about the difference between pharma-
cogenetics and PGx is that the former deals with 
single genes and the latter with the entire human 
genome [2,3]. PGx focuses on the predictive out-
come of drug interventions as opposed to genomic 
predictors of the natural course of illness, diag-
nostics and prognostics (‘genomics’). PGx is the 
study of the interaction between the drug and the 
individual in terms of drug efficacy, safety and 
pharmacokinetics (PK). It incorporates informa-
tion from across the translational spectrum, from 
gene–disease relationships through confirmatory 
clinical studies, into the development and even-
tual application of new drugs [4]. PGx offers the 
promise of delivering personalized and targeted 
drug therapy to those most likely to benefit from 
it [5–8]. PGx may also contribute to the design 
and interpretation of clinical trials and improve 
effectiveness, safety and overall benefit:risk ratio 
of drugs in development [9,10]. It has the poten-
tial for earlier arrival at informed developmental 
decisions – an alternative to the ‘trial and error’ 
approach. Both the US FDA and NIH have iden-
tified PGx as a key tool in the drug-development 
armamentarium [11,12]. This review will start 
with a general background of PGx, proceed with 
a discussion of PGx applications in early-phase 
research and conclude with recommendations for 
future development of the field. PGx stakeholders 
to whom this review is addressed include drug 
developers, clinical and preclinical investigators, 
biostatisticians, translational science experts and 
drug-development consultants, clinical research 
operators (early phase), analytics operators and 
experts, business developers, healthcare payers, 
regulators and policy makers.
History
PGx considerations, even before the term was in 
use, can be traced to ancient times [13]. The prin-
ciple of personalized treatment tailored to some-
one’s physical and physiological constitution is 
long-held [14,15]. Pythagoras’ reluctance to pass 
through fava bean fields, possibly contributing 
to his death by captors, may have been due to his 
recognition of his own glucose-6-phosphate dehy-
drogenase (G6PD) deficiency and the hemolytic 
anemia associated with consumption of fava beans 
[16,17]. Treating someone based on their body type 
or other constitutional factors, as is the practice in 
ancient Ayurveda, Chinese, Tibetan and Iranian 
traditional medicine systems, incorporates genetic 
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features into treatment considerations [13–15,18,19]. 
Evidence-based medicine may have yet to vali-
date some claims of traditional medicine, but 
these examples demonstrate that the principles 
of PGx and related personalized medicine were 
long part of medical approaches and practice. 
More recently, at the dawn of a modern trend, 
the advent of PGx as a science and development 
tool was first conceptualized by Motulsky in 1957 
[20–22]. A twin study of dicumarol pharmaco-
kinetics provided the first evidence of genetic-
based pharmaco kinetics [23]. Another example of 
a PGx-guided individualized intervention that 
may not be thought of as such but has been prac-
ticed for decades is anesthesia, where the doses of 
the anesthetics are continuously adapted to the 
individual’s signs and symptoms [24].
Background
There are many interindividual differences in 
response to drug therapy, many may not matter, 
but some do and may pertain to the interaction of 
drug with genetically determined physiological 
and pathophysiological mechanisms. The differ-
ences that matter pertain to three main catego-
ries or domains of study in PGx: PK, beneficial 
pharmacodynamics (PD; beneficial, or efficacy), 
and adverse PD (adverse or toxicity). In every 
step of PK, or the processes that govern what the 
body does to the drug (principally absorption, 
distribution, metabolism and excretion), there 
could be genetic variability in the following: 
gastro intestinal tract environment and absorp-
tion, active transport across membranes, metab-
olism, protein binding. Similarly, genetic traits 
can impact a drug’s PD, or the mechanism(s) 
governing the drug’s actions at its targets (drug-
related phenotypes [4]). The impact of inter-
species genomic differences (between rhesus 
monkeys and humans) on a drug’s target bind-
ing and consequent dramatic clinical manifesta-
tions is exemplified by the first-in-man study of 
the anti-CD28 monoclonal antibody TGN1412 
[25,26]. Genetic differences in response to drugs 
(e.g., due to CYP450 polymorphisms and G6PD 
deficiency) may be inter- or intra-ethnic [17,27–30]. 
PGx principles may inform drug developers’ 
marketing strategies and healthcare providers’ 
insurance policies [31–33].
Three main PGx approaches are applied in 
drug development:
 Candidate gene studies. Also called mono-
genetic (or simply genetic rather than the below 
genomic approaches) or targeted pathway ana-
lysis [10], these are studies of single genes known 
or hypothesized to impact specific pathways 
relevant to drug response (e.g., CYP2D6 
metabolism) [34]. These studies are hypothesis-
driven with predetermined and limited num-
bers of specific genetic associations between the 
pharmacological intervention and its outcomes. 
The disadvantage of the approach is that it may 
overlook associations with unknown and unan-
ticipated genetic candidates. The advantage is 
the small number of analyses and the often 
large effect sizes [34,35]. This has been the first 
approach to be used in PGx studies because it 
did not require access to the full human 
genome, available only since 2000 [23,34].
 Genome-wide association studies (GWAS) 
involve comparing two groups of individuals 
with differing characteristics (e.g., drug 
response) and identifying associations with 
many known genetic variants. Since the genetic 
variants are chosen without prior knowledge or 
suspicion of an association with the differing 
clinically relevant phenotypes (e.g., disease, 
responses to treatment), GWAS studies are con-
sidered an unbiased, ‘agnostic’ approach [36]. 
GWAS may assess associations of up to 1 mil-
lion genetic variants with clinically relevant 
outcomes [37]. Associations found in GWAS do 
not necessarily imply causality of the identified 
genetic marker in the variation of the pheno-
type. Hence, follow-up studies on the impact 
of modifications in gene expression on the phe-
notype are required [4]. The multiple associa-
tions studied require adequate statistical correc-
tions. With a few notable exceptions and not-
withstanding the relatively small numbers 
tested so far using GWAS, it appears that PGx 
effect sizes using GWAS are usually small [34,35].
 Whole-exome and whole-genome sequencing 
– the most comprehensive approach that ana-
lyzes the entire human genetic material for 
variants relevant to drug response [35]. It may 
help identify novel or very rare variants that 
would not be discovered via GWAS, but nev-
ertheless may need to be combined with 
GWAS to evaluate associations with drug 
response. Although interpreting such data 
would be difficult. With reduced cost of 
whole-genome sequencing (at ~US$3000 in 
2012 [4]) this approach is expected to become 
the dominant PGx approach.
Uses in clinical practice
Personalized medicine and the related term, 
individualized therapy, have been defined as 
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the practice of adapting treatment to an indi-
vidual’s medical condition, genetics, demo-
graphics, environment and lifestyle [38–40]. PGx 
addresses the genetic component of personalized 
medicine as it applies to drug therapy. Table 1 lists 
examples of successful applications of PGx in 
clinical care. The approach holds the promise 
of providing more effective, targeted treatments 
and quicker arrival at optimal care. This could 
translate into better public health benefits and 
eventually reduced hospitalizations and burden 
of illness, and increased productivity of affected 
individuals [33,41–43]. PGx has the potential to 
improve the health of vulnerable populations 
and neglected diseases [44]. Nevertheless, the 
application of PGx knowledge and principles in 
clinical practice has been slow [4,32,37,45–48]. PGx-
driven clinical practice guidelines with decision-
making algorithms informed by controlled-clin-
ical trials may increase precision, accuracy and 
relevance of recommendations and subsequent 
applicability [28,49].
n PGx use in drug development
Understanding the science of PGx: the geno-
type–phenotype interactions that are relevant 
to drug response [50] are:
 Disease genotypes and phenotypes – under-
standing the genetic origins, mechanisms and 
manifestations of illnesses is crucial to cure, 
prevention or mitigation efforts, the processes 
that influence restoration of health, and the 
design of drugs to carry out these effects.
 Drug – the therapeutic agent whose actions are 
determined by the availability of genomic-
driven targets and processes [51].
 Drug-relevant genotypes (genetic and epigen-
etic) – these are the genomic components 
(DNA and RNA) coding and determining 
drug-relevant phenotypes (see below). The 
genetic material may be germline (heritable, 
part of host constitution) or acquired 
(e.g., tumor mutations), and in either case 
may be modified by epigenetic and/or nonge-
netic elements (e.g., infections and toxins) 
temporarily or permanently [52].
 Drug-relevant phenotypes (biomarkers) – 
these are physiological and/or pathological 
phenotypes that are relevant to drug actions. 
These could be efficacy outcomes, adverse 
events, drug plasma concentrations or other 
PK/PD biomarkers. As the experience with 
gefitinib demonstrates, earlier identification of 
a predictive biomarker (e.g., the presence of 
EGFR mutation in the case of gefitinib; 
Table 1), understanding the connection between 
genetic markers and drug response can make 
drug-development programs more focused, 
effective and productive [29]. Membrane trans-
porters and genetic variations in their expres-
sion will influence PK, efficacy and safety of 
drugs [53,54]. The drug may use normal physi-
ological systems and processes to reach the 
target (e.g., chronotherapeutics – the impact 
of circadian rhythms on drug response [55]) 
and may impact normal physiological systems 
in a diseased individual.
Applications of PGx methods in 
clinical trials in early-phase clinical 
development
Application of PGx principles in drug develop-
ment is a continuous process that starts with 
discovery and continues through the drug’s 
postmarketing period [3,31,56–68]. Most PGx 
discoveries to date have been made in post-
marketing studies [10,37], but a consensus is 
being established over the utility and possibly 
the indispensable nature of PGx approaches as 
components of all stages of drug-development 
programs [4,35]. Some also recommend that all 
commonly used medications should undergo 
PGx investigation [35]. Early-phase development 
is an important landmark in the overall R&D 
process since it presents the first introduction 
of the drug to humans. It is a phase character-
ized and limited by small sample sizes and trial 
durations due to ethical and economic reasons, 
as well as by uncertainties regarding doses, out-
come measures, target populations, efficacy and 
toxicity parameters, their scope and magnitude.
Mechanistic pathways relevant to drug PD 
(efficacy and safety) affected by genetic poly-
morphisms with relevance to drug targets, and 
actions, can be determined before Phase I studies 
in humans [69]. Similarly, genetic factors affect-
ing drug metabolism, transporters and other PK 
parameters can be studied in vitro and in vivo 
prior to initiation of human studies [53,70]. Such 
findings can then be incorporated in early-phase 
human study design. For example, genetic varia-
tions in HLA detected by in vitro tests may allow 
prediction of allergic and other idiosyncratic 
adverse events in the near future [69,71]. Drug tar-
gets may also be identified through their adverse 
event profile, and what may be undesirable or 
unexpected effects in one development program 
may prove desirable and beneficial in another [51]. 
PGx offers the potential of excluding patients at 
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Figure 1. Total number of trials with pharmacogenomics outcomes (and percentage of total trials) per year in the 
clinicaltrials.gov database. Studies are divided into early phase (Phases 0, I and II) and late phase (Phases III and IV) 1999–2012. 
PGx: Pharmacogenomics.
Figure 2. The percentage of 
pharmacogenomics studies sponsored by 
industry and academia. 
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Figure 3. Number of pharmacogenomics studies per therapeutic area.  
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Analysis of clinicaltrials.gov database for pharmacogenomics in clinical trials.
Purpose: To assess the scope of application of PGx principles and outcomes in clinical trials as reflected in trials registered on 
clinicaltrials.gov. Methodology: Clinicaltrials.gov database [201] was accessed on 1 January 2013. The ‘search for studies’ feature was 
used to conduct the search with ‘pharmacogenomics’ as the keyword (also returning entries for ‘pharmacogenomic’). Each study entry 
was reviewed by the two authors and information on phase, sponsor, therapeutic area, objectives, study start date, sample size and 
end points captured. results: A total of 323 studies included PGx as outcome (primary or secondary) in the entire 14 years (1999 to 
2012) available in the clinicaltrials.gov database. This represents 0.23% of the total 138,416 studies registered during that period 
(mean: 341.4 participants per study; standard deviation: 878.2). 164 were early-phase (Phase 0, I and II) studies comprising 0.32% of 
the total 50,994 early-phase studies. PGx study numbers increased gradually from 2003 but have plateaued since 2008. Out of the 
total, 258 (80%) have been sponsored by academic institutions, 27% by industry and 7% were industry–academic collaborations. 
Oncology, at 193 studies (59.7%), was the therapeutic area with most PGx, followed by CNS (45 studies; 13.9%). See Figures 1–3. 
Conclusion: Over the 14-year period of the clinicaltrial.gov database, PGx applications in clinical trials (both general and early phase) 
remained limited with minimal growth.
PGx: Pharmacogenomics.
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risk for adverse events from clinical trials and 
eventual clinical care. PGx identification and 
exclusion of those most likely to experience an 
adverse event, as in the case of abacavir hyper-
sensitivity, have resulted in increased utilization 
and sales of this drug [72].
Utilization of PGx principles may be especially 
favorable in Phase II studies [52]. But even though 
O’Donnell et al. report only 19% positive PGx 
findings (defined as ‘worthy of additional follow-
up and validation’) in Phase I compared with 
70% in Phase II, such findings may still return 
the investment by contributing to more effective 
Phase II and Phase III designs and shorter time 
to critical developmental decisions (i.e., decisions 
influencing patent-life utilization of the drug 
under study or back-up candidates). A compre-
hensive review of PGx study designs is available 
elsewhere [69]. Randomized controlled trials in 
early-phase may be preferred for PGx studies as 
they provide more definitive information regard-
ing predictive properties of biomarkers and sub-
groups than open-labeled or single-armed trials. 
Even though randomized controlled trials are 
more expensive, they may return the investment 
by providing more precise information about 
efficacy and safety of the drug in subpopulations 
of interest and facilitate faster and more focused 
later-phase development [29]. However, if clear 
association is demonstrated between genetic poly-
morphism and drug response in in vitro studies 
such randomization may be unethical (box 1, point 
3). Adaptive designs based on PGx data collected 
in the early part of the study may improve the 
efficiency and cost–effectiveness of early-phase 
PGx trials.
Genetic profiling of subgroups at risk for 
adverse events may allow reintroduction of 
effective drugs that were withdrawn by regu-
lators owing to rare but serious adverse events 
in the postmarketing period. Such ‘rescuing’, 
‘resuscitation’ and ‘repurposing’ of drugs has 
been proposed by the NIH as a key initiative in 
the fight against stagnation in drug development 
[11,69]. Finally, PGx technologies may facilitate 
development of drugs for vulnerable populations 
and rare diseases, reduce ethnic disparities in 
applications of research findings and contribute 
to improved global public health [44].
Challenges & recommendations for 
PGx applications in early-phase trials 
box 2 outlines the challenges to PGx applications 
in early-phase development and box 3 outlines 
recommendations aimed at increasing the like-
lihood of success of such applications. To take 
full advantage of the potential contribution 
of PGx approaches, study designs and data to 
early-phase drug development, PGx strategies 
should be considered well before entry into 
human trials, preferably at least 2 years before 
anticipated first-in-man studies. This will allow 
sufficient time to gather available drug-specific 
and disease-specific genomic data (e.g., from 
target validation, in vitro and in vivo preclini-
cal studies), consultations with subject-matter 
experts and regulators, and validation of assays, 
methods and models involved [73,74]. It is fur-
ther recommended that all drugs in development 
be considered for application of PGx principles 
in their early-phase clinical development, and 
especially those meeting the criteria outlined in 
box 4. Toxicity and PK PGx biomarkers may have 
advantage over efficacy biomarkers in Phase I, 
even in oncology studies where efficacy Phase I 
studies are routine [52].
Methodological PGx considerations should 
take into account the small, short and explor-
atory nature of early-phase trials. PGx findings 
in such studies are likely to be hypothesis-gener-
ating rather than hypothesis testing, but never-
theless capable of providing mechanistic support 
of PGx effects relevant to drug response. If iden-
tified, these effects will need to be confirmed in 
definitive, larger studies in later stages of devel-
opment [10]. PGx study designs including partici-
pant selection criteria and outcomes should be 
tailored to the drug and disease under consider-
ation [10,69]. Genetic material should be collected 
from all participants if possible to increase power 
in these usually small studies, reduce selection 
bias and optimize the opportunity to identify 
and study outliers. Samples may be analyzed at 
a later stage of drug development when they can 
be combined with other sources of information 
to increase the likelihood of detecting meaning-
ful signals. Potential relevance of active metabo-
lites to efficacy and toxicity (as in the case of 
codeine, tamoxifen and clopidogrel) should be 
considered when designing PGx studies. PGx-
specific statistical methods should be used in 
study design and analyses of the data [75].
Operational standardization is crucial for the 
applicability, success and generalizability of PGx 
studies. Prospective and routine collection of 
biological samples (germline: e.g., blood, buccal 
cells; acquired mutations: e.g., tumor tissue and 
metastases) from healthy volunteers or patients 
in all clinical trials should be practiced [10,76]. 
This should be accompanied by proper, long-
term storage of DNA, RNA and tissues relevant 
to drug response. Routine PGx language should 
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be incorporated into informed consents and 
obtained, preferably, from all trial participants 
at screening to avoid introduction of selection 
bias by those who discontinue the study. Tech-
nological platforms (e.g., analytic and diagnos-
tic) suited to the drug, disease and design under 
consideration should be identified and validated 
prior to study initiation.
Business development and pipeline decision-
making and considerations may drive PGx 
approaches. PGx data may drive and con-
tribute to drug labeling and related business 
Box 1. Benefits of pharmacogenomics applications in drug development.
1. Identifying drug targets – those relevant to the drug’s efficacy, safety, pharmacokinetics
2. Study design [98]:
a. Outcomes that could be impacted by genotype variability:
i.  Pharmacokinetics – area under the curve, C
max
, T
max
, clearance, volume of distribution, 
half-life, trough drug concentrations [10]
ii.  Pharmacodynamics – biomarkers related to efficacy and/or toxicity [99]
iii.  Drug–drug interactions
iv.  Clinical outcomes – response, remission and other global measures not directly associated 
  with specific biomarkers
b. Dose selection – influenced by existing population and subpopulation information on 
dose–response and concentration–response relationships of genes relevant to the drug or 
disease under study [10,100]
c. Therapeutic window for the drug: identifying drug plasma concentrations that are between toxic 
levels (upper limit) and non-effective levels (lower limit)
d. Selection of participants (i.e., contributing to more meaningful inclusion/exclusion criteria) – for 
example: inclusion of ethnic or other subpopulations with known genetic variants relevant to 
drug response (e.g., apoE [101])
e. Prospective selection of covariates to understand gene-covariate impact on variability [10]
f.  Statistics – exploratory and hypothesis-generating approach is the rule in early-phase studies
3. Ethics: adhering to pharmacogenomic principles would enable more ethical study designs by 
limiting the testing of new medications to those most likely to benefit and least likely to experience 
adverse outcomes
4. Acquisition of information and expertise required to design future studies (i.e., Phase III and 
Phase IV)
5. Potential for genotype-specific regulatory approvals and product labeling [29,69,102]
6. Drug ‘rescue’ and ‘repurposing’ 
7. Vulnerable population and rare disease drug development [44] 
Box 2. Challenges to methodology and applications of pharmacogenomics in early-phase clinical trials.
1. Limited knowledge of genotypes and phenotypes relevant to drug response (efficacy/safety/pharmacokinetics). This may be 
particularly applicable to the development of drugs with new targets and/or mechanisms of action (applies to items next two points 
below as well)
2. Limited knowledge regarding disease phenotypes and genotypes
3. Limited knowledge regarding target populations and ethnic subpopulations relevant to drug response
4. Limited availability of technology and expertise to design and interpret PGx studies
5. Methodological hurdles – PGx signals may be too weak for the limited power of early-phase studies. Frueh argued ‘you cannot be 
personalized if you randomize’ [103] implying the goals of personalized medicine and the current gold standard of clinical research 
might be conceptually and methodologically in conflict
6. Regulatory hurdles to the standardization of PGx study methodologies and use of PGx data in drug labels and clinical practice [86,88,104]
7. Ethical hurdles – PGx studies require a definition of meaningful efficacy and toxicity thresholds. However, such thresholds are 
challenging to define [105]. Equity of access to expensive diagnostics and treatments is another ethical issue relevant to PGx applications 
[106]. Comprehension and confidentiality hurdles can limit healthy volunteer and patient participation in PGx studies [107]
8. Business and financial considerations: 
a. Limited knowledge, at earlier phases of development, about a drug’s eventual market value, extent and scope of developmental 
program
b. Limited adoption of PGx principles by drug developers. Only 27% of studies that include PGx outcomes are carried out by industry 
according to our ana lysis of the clinicaltrials.gov database 
c. Healthcare payers – although enthusiastic about PGx, are still struggling to translate study findings into effective policies [32,33]
d. Cost – the cost of whole-genome sequencing was approximately US$3000 in 2012 [4]. PGx cost is trending down while speed and 
efficiency are increasing. Whole-genome sequencing has the advantage that it only needs to be done once per lifetime
PGx: Pharmacogenomics.
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development and marketing strategies. PGx 
findings may play an important part in decisions 
to rescue or repurpose drugs based on promising 
PGx signals in subgroup analyses.
PGx in Phase 0 (microdosing) studies can be 
used to study PK parameters (absorption, distri-
bution, metabolism and excretion), transporter 
polymorphisms and imaging biomarkers [76–79]. 
An example is the utilization of PET to image 
receptor binding of the drug labeled with posi-
tron-emitting nuclides. Doses needed to image 
receptor binding are typically in the microdose 
levels, thus benefiting from regulatory leni-
ency at the pre-investigational new drug phase 
Box 3. recommendations for the application of pharmacogenomics in early-phase 
clinical trials.
A. General (including PGx applications during preclinical development)
1. Logistics:
i. Early planning – 2 years before human trials
ii. PGx considered in all POC clinical trials
iii. Drug/disease genomic data gathered
iv. Experts identified and consulted
v. Regulators engaged
vi. Validation of genotyping and phenotyping
2. Methodology:
i. Exploratory and hypothesis-generating
ii. Study types: pharmacokinetics/pharmacodynamics in healthy volunteers and/or patients; 
dose-response 
iii. Outcomes: phenotypes, genotypes of drug response, subpopulations, high-risk, outliers 
iv. PGx data collected from all participants
v. Active metabolites considered as targets
vi. Validation of genotyping and phenotyping assays
vii. Statistics: PGx-specific statistical methods 
3. Operational:
i. Routine collection of biological samples 
ii. Long-term storage of DNA, RNA and tissues 
iii. Identify technological platforms (e.g., diagnostics)
iv. Incorporation of PGx language into informed consents
4. Business development & pipeline:
i. Drug labeling
ii. Drug ‘rescue’ and ‘repurposing’
B. Phase 0 (microdosing): PGx can be used to study:
1. Pharmacokinetics (ADME – absorption, distribution, metabolism and excretion)
2. Transporter polymorphisms 
3. Imaging biomarkers 
C. Phase I: In addition to the above, PGx can be used to study:
1. Pharmacokinetics in MAD/SAD studies
2. Active metabolites
3. Toxicity
4. Drug–drug interactions
5. Efficacy (e.g., oncology) or proxy-efficacy biomarkers 
6. Healthy volunteers (unless too toxic) 
7. Validity and utility of preclinical data
8. Inform Phase II and later-phase study design 
D. Phase II: In addition to the above, PGx can be used to study:
1. Focus on efficacy biomarkers and associated genomic parameters
2. Follow-up on any signals generated in earlier studies
3. Dose range and ‘therapeutic window’
E. Validation & follow-up
1. PGx signals validated in adequately powered studies 
2. Low-frequency genotypes may preclude follow-up studies
3. PGx relevance to regulatory submissions/labeling
4. New indications, guidelines, pharmacovigilance
MAD: Multiple ascending dose; PGx: Pharmacogenomics; POC: Proof-of-concept; SAD: Single ascending dose.
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of development [80,81]. Such imaging of recep-
tor binding could help identify subpopulations 
exhibiting variability in binding to receptors of 
interest.
During Phase I, PGx can be used to study, in 
addition to the above, toxicity parameters in single 
and multiple ascending dose studies, drug–drug 
interactions, conversion to metabolically active 
compounds and, in some cases (e.g., oncol-
ogy), drug efficacy or proxy-efficacy biomark-
ers (i.e., biomarkers suggesting efficacy even in 
healthy volunteers [e.g., reduction in blood pres-
sure with antihypertensive drugs]). Phase I PGx 
studies can be used to explore magnitude and 
relevance of preclinical PGx signals pertaining 
to drug targets and mechanism of action and PK 
parameters [69]. Phase I PGx findings can inform 
Phase II and later-phase study design, including 
stratification of subpopulations, choice of doses, 
biomarkers and diagnostics [69].
In addition to the above (Phase 0 and Phase I) 
Phase II studies should focus on efficacy bio-
markers, follow-up on any signals generated in 
earlier studies (including preclinical) and help 
identify the range and therapeutic window of 
dosing regimens (especially useful for drugs 
with a narrow therapeutic index) [82]. These 
in turn should be followed by confirmation in 
large, adequately-powered and long-term stud-
ies where possible, and results incorporated, 
after regulatory approval, into product labeling, 
practice guidelines, repurposing of approved 
drugs (new indications), healthcare policies and 
pharmacovigilance programs [11,28,83,84].
regulatory role of the application of 
PGx in clinical trials &  
drug-development prgrams
n Regulatory guidelines
Regulators are promoting the utilization and 
standardization of PGx principles in drug devel-
opment. At the time of writing, the regulatory 
guideline in effect for PGx is the International 
Conference on Harmonization (ICH) E15 guide-
line: ‘Definitions for Genomic Biomarkers, Phar-
macogenomics, Pharmacogenetics, Genomic 
Data and Sample Coding Categories’ [1]. The 
guidelines have been adopted by Europe’s EMA, 
the US FDA and Japan’s Ministry of Health, 
Labour and Welfare (MHLW) in 2007, 2008 
and 2008, respectively. Application of PGx 
principles and regulations has led to inclusion 
of PGx information and recommendations in 
drug labels and treatment guidelines [28,83–87].
Recently, the FDA approved two new drugs, 
vemurafenib and crizotinib, whose development 
was strongly enhanced by application of PGx 
principles. Both anticancer drugs were tested in 
subpopulations identified by positive genomic 
markers and specially developed diagnostic 
tests, the BRAFV600E mutation and anaplastic 
lymphoma kinase tests, respectively [4].
Regulatory agencies may classify a drug as 
first-line treatment based on PGx-derived effi-
cacy and safety data (e.g., gefitinib and the 
EGFR mutation test [29]).
Early engagement with regulatory agencies 
is recommended in order to become current 
with the latest developments in this rapidly 
evolving field and take full advantage of the 
flexibility available in the regulations, scientific 
discoveries, technologies and statistical meth-
odologies relevant to PGx in early-phase clinical 
development [81,88].
economics of PGx applications in 
early-phase drug development
Will PGx applications improve the economics 
of drug development? Utilization of PGx prin-
ciples in drug development may lower drug costs 
by reducing size and length of clinical trials, 
permit earlier arrival at developmental decisions 
and increase the postapproval patent-protection 
period [89]. Hence, the impact of expensive PGx 
methodology and smaller eventual market may 
be mitigated by smaller and shorter studies, 
more efficient and cost-effective drug-develop-
ment programs. Importantly, drug-development 
programs may ground to a halt and effective 
drugs may not reach regulatory approval if 
subpopulations experience prohibitive levels 
of adverse events or efficacy signals are diluted 
by inclusion of non-responsive subpopulations. 
In addition, an ethical challenge presents itself 
Box 4. Criteria favoring inclusion of pharmacogenomics design in early-phase 
clinical trials.
1. Outcomes suggesting clear and meaningful differences among subgroups: exceptional efficacy, 
severe toxicity and outlier pharmacokinetics
2. Known drug-response phenotypes
3. Drug-response phenotypes are associated with known genomic markers
4. Existing assays for the phenotypic biomarkers and genomic markers
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regarding the administration of non-effective 
or potentially toxic treatments in face of PGx 
technologies that permit identification and pre-
venting such untoward healthcare management. 
Finally, cost–effectiveness of PGx applications 
may depend on the quality of patient care pro-
vided by the healthcare system and needs to be 
studied and demonstrated before widespread 
implementation [32,47,84].
Conclusion
The process of developing a new treatment 
involves progressive reduction of uncertainties 
regarding efficacy, safety, and, in the case of 
drugs, PK. PGx is potentially a powerful tool 
in reducing such uncertainties. Currently, PGx 
application in early-phase clinical research is 
minimal (at less than 1% of studies), station-
ary, and facing a host of challenges. We believe 
the promise of safe, effective, specific and per-
sonal treatments will serve as a powerful driver 
of PGx utilization in clinical development in 
general and early-phase research in particular 
and help overcome the challenges facing the 
PGx field. Familiarity with PGx methodologies 
and technologies, wider application and even-
tual reduced costs will lead to more efficient, 
cost-effective and productive drug-development 
programs and translation of genomic findings 
into meaningful improvements in patient care. 
We proposed a framework for the role of PGx 
in early-phase drug development and recom-
mend PGx be universally considered in study 
design, result interpretation and hypothesis gen-
eration for later-phase studies, but PGx results 
from underpowered studies should not be used 
by themselves to terminate drug-development 
programs.
Future perspective
Notwithstanding the low and stationary rate 
of PGx utilization in early-phase clinical trials 
in the past decade, we predict a growing and 
steady increase in utilization for the upcoming 
5–10 year period (2013–2023) and beyond. The 
main reason for this prediction is the belief that an 
approach that has the potential to provide valu-
able information for the development of effec-
tive, safe, specific and personal treatments will 
drive the approach past its challenges. Each of the 
challenges we have identified (limited knowledge 
about targets, genes and outcomes, limited famil-
iarity with PGx, regulatory and ethical hurdles, 
methodological challenges and high costs) is man-
ageable and improving [38,47]. In addition, current 
regulatory guidelines and efforts [10], pressures 
on industry to make drug development a more 
efficient and informed process [86,89], pressures 
from insurers to develop specific and cost-effective 
treatments [32] and public appeal for personalized 
therapeutics [90] will all serve as incentives to grow 
and establish PGx as an indispensable component 
of the clinical research and development process.
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executive summary
Background & uses in clinical practice
  Pharmacogenomics (PGx) is the study of variations of DNA and RNA characteristics as related to drug response. PGx offers the promise 
of matching the person and the illness with the optimal treatment. There is a growing number of clinical applications of PGx in routine 
healthcare and a large number of potential future applications.
Clinicaltrials.gov ana lysis
  Less than 1% of clinical trials registered at clinicaltrials.gov included PGx outcomes. The rate has been stationary for the past 6 years 
and was similar for early- and late-phase trials. Oncology accounted for approximately 60% and academia for 80% of PGx trials.
Application in early-phase clinical development
  PGx can substantially contribute to early-phase study design, selection of outcomes, stratification of participants, allocation of resources 
and improvement of clinical research ethics. Results can inform later-phase study design and pipeline developmental decisions.
Challenges & recommendations for PGx application in early-phase trials
  Challenges include: limited knowledge about targets, genes and outcomes, limited familiarity with PGx, regulatory and ethical hurdles, 
methodological challenges and high costs. We recommend PGx be universally considered in study design, result interpretation and 
hypothesis generation for later-phase studies, but PGx results from underpowered studies should not be used by themselves to 
terminate drug-development programs.
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